Ken Griffin Astrazeneca PLC Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Astrazeneca PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 1,754,600 shares of AZN stock, worth $137 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,754,600

Previous 1,191,500 47.26%

Holding current value

$137 Million

Previous $80.2 Million 48.14%

% of portfolio

0.02%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$61.03 - $69.57 $3.65 Million - $4.16 Million	59,730 Added 13.92%	488,852 $33.1 Million
Q4 2023 Feb 14, 2024	SELL	$61.89 - $69.28 $21.3 Million - $23.9 Million	-344,677 Reduced 44.54%	429,122 $28.9 Million
Q3 2023 Nov 14, 2023	BUY	$64.85 - $71.7 $9.23 Million - $10.2 Million	142,402 Added 22.55%	773,799 $52.4 Million
Q2 2023 Aug 14, 2023	BUY	$69.91 - $75.81 $19.6 Million - $21.3 Million	280,394 Added 79.88%	631,397 $45.2 Million
Q1 2023 May 15, 2023	BUY	$63.15 - $71.6 $2.26 Million - $2.56 Million	35,800 Added 11.36%	351,003 $24.4 Million

Q4 2022 Feb 14, 2023	SELL	$54.21 - $70.44 $71.9 Million - $93.4 Million	-1,325,457 Reduced 80.79%	315,203 $21.4 Million
Q3 2022 Nov 14, 2022	BUY	$53.02 - $135.75 $86.3 Million - $221 Million	1,627,476 Added 12344.33%	1,640,660 $90 Million
Q2 2022 Aug 15, 2022	SELL	$59.26 - $71.14 $254,343 - $305,332	-4,292 Reduced 24.56%	13,184 $871,000
Q1 2022 May 16, 2022	SELL	$55.72 - $67.12 $64.6 Million - $77.8 Million	-1,158,953 Reduced 98.51%	17,476 $1.16 Million
Q4 2021 Feb 14, 2022	BUY	$54.02 - $63.83 $11.1 Million - $13.2 Million	206,057 Added 21.23%	1,176,429 $68.5 Million
Q3 2021 Nov 15, 2021	SELL	$55.56 - $60.79 $14.6 Million - $15.9 Million	-262,319 Reduced 21.28%	970,372 $58.3 Million
Q2 2021 Aug 16, 2021	SELL	$48.42 - $60.18 $55.5 Million - $69 Million	-1,146,945 Reduced 48.2%	1,232,691 $73.8 Million
Q1 2021 May 17, 2021	SELL	$47.16 - $54.44 $66.3 Million - $76.5 Million	-1,406,044 Reduced 37.14%	2,379,636 $118 Million
Q4 2020 Feb 16, 2021	BUY	$48.52 - $58.02 $143 Million - $171 Million	2,950,678 Added 353.37%	3,785,680 $189 Million
Q3 2020 Nov 16, 2020	SELL	$53.07 - $61.1 $5.03 Million - $5.79 Million	-94,689 Reduced 10.18%	835,002 $45.8 Million
Q2 2020 Aug 14, 2020	SELL	$43.1 - $55.31 $36.6 Million - $47 Million	-849,052 Reduced 47.73%	929,691 $49.2 Million
Q1 2020 May 15, 2020	BUY	$37.79 - $51.33 $48.5 Million - $65.8 Million	1,282,558 Added 258.48%	1,778,743 $79.4 Million
Q4 2019 Feb 14, 2020	SELL	$42.46 - $50.46 $43.3 Million - $51.4 Million	-1,018,753 Reduced 67.25%	496,185 $24.7 Million
Q3 2019 Nov 14, 2019	BUY	$40.12 - $45.47 $9.11 Million - $10.3 Million	227,174 Added 17.64%	1,514,938 $67.5 Million
Q2 2019 Aug 14, 2019	SELL	$37.28 - $41.68 $6.43 Million - $7.19 Million	-172,404 Reduced 11.81%	1,287,764 $53.2 Million
Q1 2019 May 15, 2019	BUY	$35.49 - $43.02 $41.5 Million - $50.3 Million	1,168,996 Added 401.48%	1,460,168 $0
Q4 2018 Feb 14, 2019	SELL	$36.86 - $41.49 $76.9 Million - $86.6 Million	-2,086,532 Reduced 87.75%	291,172 $11.1 Million
Q3 2018 Nov 13, 2018	SELL	$34.76 - $39.72 $1.52 Million - $1.74 Million	-43,696 Reduced 1.8%	2,377,704 $0
Q2 2018 Aug 10, 2018	BUY	$34.55 - $37.05 $75.3 Million - $80.7 Million	2,178,073 Added 895.12%	2,421,400 $0
Q1 2018 May 11, 2018	BUY	$32.97 - $36.63 $7.08 Million - $7.87 Million	214,806 Added 753.15%	243,327 $8.51 Million
Q4 2017 Feb 09, 2018	SELL	$32.09 - $34.78 $19.1 Million - $20.8 Million	-596,615 Reduced 95.44%	28,521 $990,000
Q3 2017 Nov 09, 2017	BUY	$28.96 - $34.0 $18.1 Million - $21.3 Million	625,136	625,136 $21.2 Million

Others Institutions Holding AZN

# of Institutions

1,244

Shares Held

477M

Call Options Held

5.99M

Put Options Held

5.24M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $242B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account